The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA
Status:
Completed
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Topical Brimonidine is a well-established topical antigalucoma, ocular hypotensive
therapeutic that has been in use since 1996. Brimonidine stands out among other topical
ocular hypotensives in that it has a neuroprotective effect that is independent of IOP
reduction. This has been demonstrated in multiple animal and human controlled studies both in
vivo and in vitro. The mechanisms proposed so far to account for this neuroprotection focus
mainly on molecular level antiapoptotic effects and modulation of some excitatory stimuli
like glutamate. In this study we try to test the hypothesis that a positive hemodynamic
profile of Brimonidine on ocular blood flow may be responsible at least in part for its
unique neuroprotective effects.